Life Enhancing Allografts
Origin Biologics is re-inventing the Allograft Contract Manufacturing model to be more customer-centric, cost-effective and flexible.

In 2014, the Nevada Donor Network and Australian Biotechnologies began to investigate how they could enhance the gift of tissue donation. This partnership included a vision to build a state-of-the-art facility, whereby the Nevada Donor Network could honor their tissue donors and Australian Biotechnologies could bring tissue processing to the American community. As a result, Origin Biologics was formed.

Our extensive experience in allograft processing, and the support of several tissue procurement organizations, will allow for the immediate processing of up to 100,000 allografts (1,600 donors per annum), on completion of our new facility in Q4, 2019.

We are focused on providing the highest quality musculoskeletal implants that will accelerate and restore the biological and mechanical functionality of diseased, degenerative and trauma induced orthopedic and spinal defects. As a result, we will be seeking partnerships with spinal and orthopedic device companies to develop and contract manufacture allograft implants.

Musculoskeletal tissue manufacturing begins with the lasting gift of human cell and tissue donation. In a family’s darkest hour, this gift can make a huge impact. A single tissue donation can enhance and improve the lives of up to 50 recipients.

A total of fifty-eight (58) registered Organ Procurement Organizations (OPO’s) are currently responsible for honoring these donors’ wishes for transplant and/or medical research. Consenting donors, their next-of-kin and a rigorous screening process overseen by the Federally mandated donation program, allow human cell, tissue and cellular and tissue-based products (HCT/P’s) to be produced.

Origin Biologics will be fully operational in Q4, 2019, in Las Vegas, Nevada. Our 22,000ft² manufacturing and distribution center will provide the highest quality musculoskeletal implants to precise specifications, using agile manufacturing platforms. These platforms will decrease time and cost to market while providing excellent clinical outcomes.

ORIGIN BIOLOGICS HIGHLIGHTS

- Located within 15 minutes of the seventh busiest airport in the United States (McCarran International - LAS)
- 22,000ft² manufacturing and distribution center including:
  - Five modular cleanrooms
    - Three ISO Class 5 manufacturing rooms
    - Two ISO Class 6 manufacturing rooms
    - Single shift capacity = 1,250 donors/annum
    - Maximum capacity = 3,000 donors/annum
  - Fully staffed and equipped Central Supply, which allows tight control over cleaning and steam sterilization of processing equipment
- Compliance
  - Once operational, Origin Biologics will be an FDA registered facility for the manufacturing, storage and distribution of HCT/P’s and medical devices for implantation
  - We will also be registering with the Therapeutic Goods Administration (TGA), American Association of Tissue Banks (AATB) and the appropriate ISO certifications
- Donor access:
  - Stable 1,600 donor supply and negotiating for an additional 1,500 donors
- Construction complete = Q4 2018
- Validation begins Q4 2018 through Q3 2019
- Technical transfer programs begin Q2 2019
- Commercial launch Q4 2019
Donors

It is imperative to honor and execute in the best interest of the donor and when appropriate their next-of-kins’ wishes. We strive to maximize their generous gift of donation, and pass along the powerful restorative and regenerative capacity of musculoskeletal tissues, to as many patients as possible, thereby providing the lasting gift.

Quality

The guiding operational principal of Origin Biologics is our quality system and design control process, where we leverage the power of technology, to improve historically burdensome and tedious transactions and bottlenecks, therefore reducing it to a lean, efficient and streamlined electronic process.

Safety

Building on a solid quality foundation, we understand the critical nature of what we do. We have built rigorous screening programs, vendor and personnel training qualifications, as well as designed both mechanical and chemical manufacturing processes, and validated terminal sterilization procedures, to greatly minimize the risk of disease transmission.

Customers

We seek to understand and develop intimate relationships with a small network of customers, so that we can provide the highest level of service to each partner, while allowing for sustainable future product extensions, as well as new product line growth.

Efficiency

Data driven metrics, a relentless focus on continual improvement and a heavy dose of technological infrastructure, will drive value for our customers, including improved efficiencies in design control, technical transfer, manufacturing, supply chain and lean distribution processes.

Innovation

Innovation isn’t simply the number of patents on your walls, it’s how you create value in a dynamic and highly competitive market. It’s creating new opportunities and providing a distinct market advantage for you and your partners.